middle.news
How Is Zelira Advancing HOPE 1 Trials Amid Tight Cash and New Loans?
2:51pm on Monday 27th of October, 2025 AEDT
•
Biotechnology
Read Story
How Is Zelira Advancing HOPE 1 Trials Amid Tight Cash and New Loans?
2:51pm on Monday 27th of October, 2025 AEDT
Key Points
Completed FDA IND submission for HOPE 1 Phase 1 clinical trials
Secured $650,000 non-dilutive loan against FY25 R&D tax incentive
Directors provided USD 150,000 in unsecured loans on attractive terms
Q1 FY2026 cash burn of $711,000 with cash balance at $172,000
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Zelira Therapeutics (ASX:ZLD)
OPEN ARTICLE